p53 immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix

J Pathol. 1993 Apr;169(4):425-30. doi: 10.1002/path.1711690407.

Abstract

Immunoreactivity for the tumour suppressor gene product p53 is commonly found in many different human malignancies and few premalignant lesions. Data on cervical neoplasms, however, are still lacking. We retrospectively investigated p53 immunoreactivity in 92 lesions of the uterine cervix, including 44 cases of chronic cervicitis, 29 squamous intraepithelial lesions (SILs), and 19 invasive carcinomas. p53 immunoreactivity, confined to the basal cell layer, was detected in 74 per cent of cases showing chronic cervicitis and in all cases with low-grade SILs. Conversely, suprabasal and/or diffuse p53 immunoreactivity was exclusively demonstrated in 25 per cent of high-grade SILs and in 74 per cent of invasive carcinomas. The results of this investigation document a high prevalence of p53-immunoreactive malignant tumours of the uterine cervix. In high-grade SILs, p53-immunoreactive cells paralleled the height of involvement by dysplastic changes within the squamous epithelium. A prolonged half-life of the protein is the most likely explanation for the occurrence of p53 immunoreactivity in neoplastic cells. The unexpected finding of p53-immunoreactive cells in inflammatory lesions, though possibly related to an increased proliferation rate of the basal cell compartment, requires further study and underlines the need for a careful approach to p53 immunocytochemistry.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / chemistry
  • Carcinoma in Situ / chemistry
  • Carcinoma, Squamous Cell / chemistry
  • Cervix Uteri / chemistry*
  • Chronic Disease
  • Female
  • Humans
  • Immunohistochemistry
  • Prevalence
  • Retrospective Studies
  • Tumor Suppressor Protein p53 / analysis*
  • Uterine Cervical Neoplasms / chemistry*
  • Uterine Cervicitis / metabolism*

Substances

  • Tumor Suppressor Protein p53